Annals of Surgical Oncology

, Volume 15, Issue 6, pp 1600–1608 | Cite as

Lymph Node Ratio: Role in the Staging of Node-Positive Colon Cancer

  • Jiping Wang
  • James M. Hassett
  • Merril T. Dayton
  • Mahmoud N. Kulaylat
Gastrointestinal Oncology



Recent literature has shown that lymph node ratio (LNR) is superior to the number of positive lymph nodes (pLNs) in predicting the prognosis in several malignances other than colon cancer. We hypothesize that LNR may play a similar role in stage III colon cancer.


We included 24,477 stage III colon cancer cases from the Surveillance, Epidemiology, and End Results cancer registry. Patients were categorized into four groups, LNR1 to 4, according to cutoff points \( \raise0.5ex\hbox{$\scriptstyle 1$} \kern-0.1em/\kern-0.15em \lower0.25ex\hbox{$\scriptstyle {14}$} \), 0.25, and 0.50. Kaplan-Meier and Cox proportional hazard model were used to evaluate the prognostic effect and estimate the relative risk (RR) and 95% confidence interval (CI) of LNR.


The 5-year survival for patients with stage IIIA, IIIB, and IIIC was 71.3%, 51.7%, and 34.0%, respectively (P < .0001). There was no survival difference among LNR1 to LNR4 for stage IIIA patients. In stage IIIB patients, the 5-year survival for those with LNR1 to LNR4 was 63.5%, 54.7%, 44.4%, and 34.2%, respectively (P < .0001). In stage IIIC patients, the 5-year survival for those with LNR2 to LNR4 was 49.6%, 41.7%, and 25.2%, respectively (P < .0001). LNR is an independent predictor of survival after adjusting patient’s age, tumor size, tumor grade, race, number of pLNs, and total number of LNs harvested. (RR 2.30, 95% CI 2.08–2.55).


Patients with stage IIIB and IIIC colon cancer represent a heterogeneous group of patients with the majority either overstaged or understaged. LNR is a more accurate prognostic method for stage III colon cancer patients. We propose an algorithm to incorporate LNR into current AJCC staging system.


Colon cancer Stage Lymph node Lymph node ratio Prognosis 


  1. 1.
  2. 2.
    Hutter RVP. At last: worldwide agreement on the staging of cancer. Arch Surg 1987; 122:1235–9PubMedGoogle Scholar
  3. 3.
    AJCC Cancer Staging Manual, 6th ed. New York: Springer, 2002Google Scholar
  4. 4.
    Greene FL, Stewart AK, Norton J. A new TNM staging strategy for node-positive (stage III) colon cancer: An analysis of 50,042 patients. Ann Surg 2002; 236:416–21PubMedCrossRefGoogle Scholar
  5. 5.
    Berger AC, Sigurdson ER, LeVoyer T, et al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 2005; 23:8706–12PubMedCrossRefGoogle Scholar
  6. 6.
    Yu W, Choi GS, Wang I, et al. Comparison of five systems for staging lymph node metastasis in gastric cancer. Br J Surg 1997; 84:1305–9PubMedCrossRefGoogle Scholar
  7. 7.
    Kodera Y, Yamamura Y, Shimizu Y, et al. Lymph node status assessment for gastric carcinoma: is the number of metastatic lymph nodes really practical as a parameter for N categories in the TNM classification? J Surg Oncol 1998; 69:15–20PubMedCrossRefGoogle Scholar
  8. 8.
    Siewert JR, Bottcher FK, Stein HJ, et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998; 228:449–61PubMedCrossRefGoogle Scholar
  9. 9.
    Inoue K, Nakane Y, Liyama H, et al. The superiority of ratio-based lymph node staging in gastric carcinoma. Ann Surg Oncol 2002; 9:27–34PubMedCrossRefGoogle Scholar
  10. 10.
    van der Wal BC, Butzelaar RM, van der Meij S, et al. Axillary lymph node ratio and total number of removed lymph nodes: Predictors of survival in stage I and II breast cancer. Eur J Surg Oncol 2002; 28:481–9PubMedCrossRefGoogle Scholar
  11. 11.
    Megale Costa LJ, Soares HP, Gaspar HA, et al. Ratio between positive lymph nodes and total dissected axillaries lymph nodes as an independent prognostic factor for disease-free survival in patients with breast cancer. Am J Clin Oncol 2004; 27:304–6PubMedCrossRefGoogle Scholar
  12. 12.
    Vinh-Hung V, Verschraegen C, Promish DI, et al. Ratios of involved nodes in early breast cancer. Breast Cancer Res 2004; 6:R680–8PubMedCrossRefGoogle Scholar
  13. 13.
    Voordeckers M, Vinh-Hung V, Van de Steene J, et al. The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol 2004; 70:225–30PubMedCrossRefGoogle Scholar
  14. 14.
    Truong PT, Berthelet E, Lee J, et al. Prognostic significance of the percentage of positive/dissected axillary nodes in breast cancer relapse and survival in patients with 1–3 positive axillary nodes. Cancer 2005; 103:2006–14PubMedCrossRefGoogle Scholar
  15. 15.
    Woodward WA, Vinh-Hung V, Ueno NT, et al. Prognostic value of nodal ratios in node-positive breast cancer. J Clin Oncol 2006; 24:2910–6PubMedCrossRefGoogle Scholar
  16. 16.
    De Ridder M, Vinh-Hung V, Van Nieuwenhove Y, et al. Prognostic value of the lymph node ratio in node positive colon cancer. Gut 2006; 55:1681PubMedCrossRefGoogle Scholar
  17. 17.
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457–81CrossRefGoogle Scholar
  18. 18.
    Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143:29–36PubMedGoogle Scholar
  19. 19.
    Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34:187–220Google Scholar
  20. 20.
    Chang GJ, Rodriguez-Bigas MA, Skibber JM, et al. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 2007; 99:433–41PubMedCrossRefGoogle Scholar
  21. 21.
    Marchet A, Mocellin S, Ambrosi A, et al. The ratio between metastasis and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients. Ann Surg 2007; 245:543–52PubMedCrossRefGoogle Scholar
  22. 22.
    Walker MJ, Osborne MD, Young DC, et al: The natural history of breast cancer with more than 10 positive nodes. Am J Surg 1995; 169:575–9PubMedCrossRefGoogle Scholar
  23. 23.
    Gurkaynay M, Yildiz F, Atahan L. T3N0M0 breast cancer patients: A subgroup with favorable prognosis. Turkish J. Cancer 2003; 33:144–9Google Scholar
  24. 24.
    Wong JH, Severino R, Honnerbier MB, et al. Number of nodes examined and staging accuracy in colorectal carcinoma. J Clin Oncol 1999; 17:2896–900PubMedGoogle Scholar
  25. 25.
    Wong JH, Johnson DS, Hemmings D, et al. Assessing the quality of colorectal cancer staging: documenting the process in improving the staging of node negative cororectal cancer. Arch Surg 2005; 140:881–6PubMedCrossRefGoogle Scholar
  26. 26.
    Swanson RS, Compton CC, Stewart AK, Bland KI. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 2003; 10:65–71PubMedCrossRefGoogle Scholar
  27. 27.
    Tepper JE, O’Connell MJ, Niedzwiecki D, et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 2001;19:157–63PubMedGoogle Scholar
  28. 28.
    Compton C, Fenoglio-Preiser CM, Pettigrew N, et al. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 2000; 88:1739–57PubMedCrossRefGoogle Scholar
  29. 29.
    Yarbro JW, Page DL, Fielding LP, et al. American Joint Committee on Cancer prognostic factors consensus conference. Cancer 1999; 86:2436–46PubMedCrossRefGoogle Scholar
  30. 30.
    Goldstein NS, Weldon S, Coffey M, et al. Lymph node recovery from colorectal resection specimens removed from adenocarcinoma: Trends over time and a recommendation for a minimum number of lymph nodes to be recovered. Am J Clin Pathol 1996; 106:209–16PubMedGoogle Scholar
  31. 31.
    Kim J, Huynh R, Abraham I, et al. Number of lymph nodes examined and its impact on colorectal cancer staging. Am Surg 2006; 72:902–5PubMedGoogle Scholar
  32. 32.
    Berberoglu U. Prognostic significance of total lymph node number in patients with T1–4N0M0 colorectal cancer. Hepatogastroenterology 2004; 51:1689–93PubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2007

Authors and Affiliations

  • Jiping Wang
    • 1
    • 2
  • James M. Hassett
    • 1
  • Merril T. Dayton
    • 1
  • Mahmoud N. Kulaylat
    • 1
  1. 1.Department of SurgeryUniversity at Buffalo, State University of New YorkBuffaloNew York
  2. 2.Department of BiostatisticsUniversity at Buffalo, State University of New YorkBuffaloNew York

Personalised recommendations